MedTrace Logo

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

NCT06358430 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-05-20

No results posted yet for this study

Summary

To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.

Conditions

Interventions

DRUG

Fludarabine Phosphate

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

Cetuximab

Given by IV

DRUG

TROP2-CAR-NK Cells

Given by IV

DRUG

Rimiducid (AP1903)

Given by IV

PROCEDURE

Lymphodepleting Chemotherapy

Given by Chemotherapy

Sponsors & Collaborators

  • Bellicum Pharmaceuticals, Inc.

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Maria Pia Morelli, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2029-01-18
Completion
2029-01-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06358430 on ClinicalTrials.gov